Cargando…

A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer

Taxane chemotherapy represents the standard of care in the second-line setting for non-small cell lung cancer (NSCLC) patients, but immunotherapy agents pose great challenges. Whether immunotherapy/chemotherapy alone or combination therapy has more benefits remains controversial. In this study, we p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xin-Xiu, Lin, Guo-He, Wang, Bi-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666094/ https://www.ncbi.nlm.nih.gov/pubmed/36397323 http://dx.doi.org/10.1097/MD.0000000000031751

Ejemplares similares

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

The Efficacy of Taxanes- and Oxaliplatin-Based Chemotherapy in the Treatment of Gastric Cancer After D2 Gastrectomy for Different Lauren Types
por: Zheng, Zhen, et al.
Publicado: (2016)

Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
por: Kim, Se Hyun, et al.
Publicado: (2017)

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2020)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients
por: Lopez, Anthony, et al.
Publicado: (2020)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
por: Chen, Yu Jie, et al.
Publicado: (2015)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy
por: Liu, Xiaofan, et al.
Publicado: (2017)

Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016)

Comparison between atlas and convolutional neural network based automatic segmentation of multiple organs at risk in non-small cell lung cancer
por: Zhang, Tao, et al.
Publicado: (2020)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016)

Acupuncture therapy for preventing the nausea and vomiting following high emetic risk chemotherapy: A protocol for systematic review and Bayesian Network meta-analysis
por: Deng, Yi-ran, et al.
Publicado: (2020)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report
por: Jung, Sung Ui, et al.
Publicado: (2021)

Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report
por: Guo, Wenliang, et al.
Publicado: (2023)

Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer: A Meta-Analysis of Randomized Trials
por: Zheng, Ruinian, et al.
Publicado: (2015)

The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: A meta-analysis
por: Huang, Yang, et al.
Publicado: (2021)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
por: Xu, Shuyuan, et al.
Publicado: (2019)

Platinum versus immunotherapy for early resectable non-small cell lung cancer: A protocol for systematic review and meta analysis
por: Tong, Zhangwei, et al.
Publicado: (2020)

Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
por: Nong, Jingying, et al.
Publicado: (2021)

Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis
por: Huang, Peng, et al.
Publicado: (2023)

The effectiveness and safety of lienal polypeptide combined with chemotherapy or chemoradiotherapy for non-small cell lung cancer patients in real world
por: Wang, Zhe, et al.
Publicado: (2021)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016)

Does Early PET/CT Assesment of Response to Chemotherapy Predicts Survival in Patients With Advanced Stage Non-Small-Cell Lung Cancer?
por: Ordu, Cetin, et al.
Publicado: (2014)

A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy: A case report and review of the literature
por: Pan, Yong, et al.
Publicado: (2017)

The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer
por: Moon, Ji Young, et al.
Publicado: (2018)

Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience
por: Pehlivan, Metin, et al.
Publicado: (2023)

Optimum cycles of induction chemotherapy in concurrent chemo-radiotherapy management of unresectable stage III non-small cell lung cancer: Results from a single institutional database
por: Yacouba, Mohamed Bassirou Moukeila, et al.
Publicado: (2023)

Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis
por: Zheng, Yu, et al.
Publicado: (2017)

Clinical outcome in lung cancer with a second malignancy: The time sequence matters
por: Lu, Ming-Shian, et al.
Publicado: (2016)

Integrated analysis of competitive endogenous RNA networks in elder patients with non-small cell lung cancer
por: Chen, Zi, et al.
Publicado: (2023)

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
por: Li, Luzhen, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
por: Kutlu, Yasin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6mpfls654igk03hngrto831cpl